ArticleAnnals of hematology2025
The impact of CD81 on immune cells and clinical prognosis in multiple myeloma.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Multiple myeloma (MM) is a refractory hematologic malignancy driven by clonal plasma cell proliferation and a complex bone marrow microenvironment. CD81, a tetraspanin protein, has been implicated in immune regulation and cancer progression, but its role in MM remains unclear. This study investigated the prognostic significance of CD81 expression and its relationship with immune cells in 178 newly diagnosed MM patients. CD81 positivity (60.67%) was associated with reduced overall survival (OS) but not progression-free survival (PFS). High CD81 expression correlated with decreased peripheral CD8 + T cell counts and increased M2 macrophage infiltration (CD206+), both linked to poorer outcomes. Conversely, high CD68 expression (pan-macrophage marker) was associated with improved prognosis, potentially reflecting favorable M1 macrophage activity. These findings highlight CD81 as a prognostic marker in MM, influencing immune cell dynamics and clinical outcomes. The interplay between CD81, M2 macrophages, and CD8 + T cells underscores the complexity of the MM immune microenvironment, suggesting novel therapeutic targets. Further studies are needed to elucidate CD81's mechanistic role in immune modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.